Maintenance Venetoclax in AML Fit Patients
Maintenance Venetoclax Based Therapy Post Complete Remission in AML Fit Patients
Sohag University
80 participants
Sep 1, 2025
INTERVENTIONAL
Conditions
Summary
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
Eligibility
Inclusion Criteria1
- Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .
Exclusion Criteria1
- Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation
Interventions
SC Cytarabine (20 mg) administrated on days 1-7 ,,Venetoclax (100 mg ) administrated on days 1-7,,Voriconazole 200 mg 1x2 administrated on days , Best supportive care as needed . Up to 12 cycles or until patients undergo bone marrow transplantation
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07244367